Class Action Lawsuit - Levi & Korsinsky, LLP notifies investors in Applied Therapeutics, Inc (NASDAQ: APLT) of a class action securities lawsuit seeking to recover losses for investors affected by alleged securities fraud between January 3, 2024 and December 2, 2024 [1] Case Details - Applied Therapeutics received a Complete Response Letter (CRL) from the FDA on November 27, 2024 for its New Drug Application (NDA) for govorestat, citing deficiencies in the clinical application [2] - Following the CRL announcement, Applied Therapeutics' stock price declined from 8 57 per share on November 27, 2024, and further to 1 75 per share on December 2, 2024, a total decline of more than 80% [2] - On December 2, 2024, Applied Therapeutics disclosed a "warning letter" from the FDA regarding clinical trial issues, causing the stock price to fall further to 1 38 per share on December 4, 2024, and $1 29 per share on December 5, 2024 [2] Next Steps for Investors - Investors who suffered losses in Applied Therapeutics during the relevant time frame have until February 18, 2025 to request the Court appoint them as lead plaintiff [3] - Class members may be entitled to compensation without payment of any out-of-pocket costs or fees [3] Levi & Korsinsky Expertise - Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders over the past 20 years and has a team of over 70 employees [4] - The firm has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States for seven consecutive years [4]
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics Lawsuit - APLT